Diabetes mellitus is often associated with cardiovascular complications, which is the leading cause of morbidity and mortality among diabetes patients, but little is known about the mechanism that connects diabetes to the development of cardiovascular dysfunction.
INTRODUCTION
By 2025, the number of individuals with diabetes worldwide is predicted to be ~300 million. Cardiovascular disease accounts for 80% of death among diabetic patients, which often leads to heart failure 1 . Diabetic cardiomyopathy (DCM) is characterized by changes in myocardial structure and function, which is known to associate with a variety of complications, including advanced glycation end products, fibrosis, increased fatty acid (FA) utilisation, lipotoxicity, elevated apoptotic and necrotic cell death, impaired Ca 2+ balance, mitochondrial dysfunction, altered myocardial insulin signalling, and oxidative and endoplasmic reticulum stress 2 . However, it has been virtually unclear about the causal relationships among these complications.
Despite the fact that diabetic conditions are linked to the development of cardiac dysfunction and prognosis is worse for heart failure patients with abnormal levels of glycated haemoglobin, intensive glycemic control has been found to be insufficient in reducing the risk of heart failure among diabetes patients 3 , implying that diabetes-associated cardiac dysfunction may be induced by other metabolic triggers. In fact, diabetes has been characterized by hyperlipidemia and hyperinsulinemia, both of which are known to precede pancreatic cell failure 4 . Resulting hyperglycemia can further enhance fatty acid (FA) uptake and myocardial steatosis 5 , which may lead a vicious cycle between elevated glucose toxicity and lipotoxicity to drive the development of heart failure. In terms of the treatment, though recent studies have demonstrated that sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin, a new drug for diabetes mellitus, reduced the risk of cardiovascular death or hospitalized heart failure in patients with type 2 diabetes mellitus and an elevated risk of cardiovascular disease, the exact mechanisms and whether it functions on diabetic cardiomyopathy are still not defined 3, 6 .
MicroRNA (miRNA) is a class of small (≈22 nt) non-coding RNAs with well-established functions in cancer, metabolic disorders, and cardiovascular diseases. A recent study identified 316 miRNAs dysregulated in the heart of streptozotocin-induced diabetes mice, and importantly, glycaemic control was found to be unable to rescue such hyperglycaemia-induced miRNA expression in diabetic heart 7 , suggesting a potential contribution of miRNAs to the development of diabetes-induced cardiac dysfunction. miRNAs typically suppress gene expression at post-transcriptional levels in the cytoplasm, but increasing evidence also suggests roles of miRNAs in the nucleus as well as in the mitochondria 8, 9 . Despite their clear linkage to various diseases, it has remained largely elusive about how specific miRNAs might contribute to defined disease pathways.
In this study, we report the up-regulation of the miRNA miR-320 in the failing heart of diabetes mice (db/db) as well as in patients with diabetes. Unexpectedly, we found that miR-320 is efficiently translocated to the nucleus where it enhances CD36 transcription, leading to enhanced uptake of free fatty acids (FFA), thereby causing myocardial lipotoxicity. We demonstrated that a miR-320 tough decoy (TuD) delivered by recombinant adeno-associated virus (rAAV) is able to rescue the cardiac dysfunction in diabetes mice, suggesting a potential therapy for diabetes-associated cardiac dysfunction.
METHODS
An expanded version of the Methods, including detailed experimental procedures on animals, microarrays, high-throughput sequencing, a list of PCR primers and antibodies, are presented in the online-only Data Supplementary.
The raw sequencing and microarray data that support the findings of this study are available from the corresponding authors upon request.
Ethics statement.
Human heart and plasma samples were collected at Tongji Hospital (Wuhan, China) between January 2012 and October 2014. The study, approved by the Ethics Review Board of Tongji Hospital and Tongji Medical College, conforms to the principles outlined in the Declaration of Helsinki. Written, informed consent was obtained from individual subjects or their immediate family members in cases of incapacitation. The animal study was carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Animal Research Committee of Tongji College.
Transcriptome analysis and miRNA profiling.
miRNA and mRNA sequencing and data analysis were performed by Personal Biotechnology Co. (Shanghai, China). Microarray analysis on human heart miRNAs was performed by Kangcheng Bio-tech (Shanghai, China) using the Exiqon miRCURY LNA™ microRNA Arrays (7th generation). Microarray analysis of heart samples from db/db and wt mice were carried out at CapitalBio (Beijing, China) on GeneChip TM Mouse Genome 430 2.0 Arrays from Affymetrix (Santa Clara, CA). The methods and partial results were described in our previous work 10 .
Generation of miR-320 transgenic (tg) mice and in situ hybridization.
To generate miR-320 tg mice, a DNA fragment containing murine miR-320 was inserted into the pUBC vector for expression under the control of the ubiquitin C promoter. Microinjection was performed according to standard protocols. miR-320 tg mice were back-crossed into the C57BL/6 background for six generations, yielding wt and miR-320 tg mice that were > 95% of the C57BL/6 genotype. The primers for genotyping miR-320 tg mice were 5'-CCACTGCTTACTGGCTTATCG-3' (forward) and R 5'-ATGAAGCACCTCCGCTGAG-3' (reverse). miRNA in situ hybridisation was performed on formalinfixed and paraffin-embedded tissue specimens as previously described 11 .
Prediction of miRNA targets. The RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid/submission.html) and miRBase (http://www.mirbase.org/) websites were used for miR-320 target prediction. Base-pairing at least 7 consecutive nucleotides (allowing G:U wobbles) and a minimum free energy of hybridization lower than -20 kcal/mol, which have been shown to be sufficient for formation of a miRNA/mRNA complex 12 , were used as a cut-off to identify potential miRNA targets.
rAAV administration.
Male wt and db/db mice (from the Model Animal Research Center of Nanjing University, China) were divided into rAAV9 treatment (rAAV-miR-Random, rAAV-miR-320, rAAV-miR-320 TUD (inhibitor) and rAAV9-tnt-treatment (rAAV-tnt-miR-Random, rAAV-tnt-miR-320, and rAAV-tnt-miR-320TUD, rAAV-tnt-CD36, rAAV-tnt-CD36-shRNA) groups. The detailed experimental procedure on animals is presented in the online-only Data Supplementary.
Statistical analysis.
Tests for statistical significance were computed using the Prism version 8.0.2 software (GraphPad Software, San Diego, CA) with a probability value of p < 0.05 considered significant. Each data set, irrespective of the sample size, was tested for normality typically using the Shapiro-Wilk test. Thereafter, a parametric or non-parametric test was chosen as appropriate. Statistical analyses were then performed with Two tailed student's t-test (parametric unpaired or paired, two group of analysis), Wilcoxon signed-rank test (nonparametric paired, two group of analysis), Mann-Whitney U test (non-parametric unpaired, two group of analysis), one-way ANOVA combined with bonferroni multiple comparisons (comparisons between more than two groups, parametric unpaired) and Kruskal-Wallis ANOVA test with Dunn's multiple comparisons test (comparisons between more than two groups, non-parametric unpaired). Two-way ANOVA followed by Dunnett post hoc test were used in the in vivo studies on the same continuous mice when multiple time points were involved. Data are represented as mean ± SEM, unless otherwise stated. A value of p (or corrected p in case of multiple groups) < 0.05 was considered to be statistically significant.
RESULTS

miR-320 is up-regulated in cardiomyocytes under diabetic conditions.
The leptin receptor-deficient db/db mouse is a well-established rodent model for type 2 diabetes and diabetic complications 13 . Cardiac function is clearly compromised at the age of 6 months in these mice 14 .
To identify dysregulated miRNAs in this diabetes-induced cardiac dysfunction model, we carried out small RNA sequencing on hearts from 6-month-old db/db mice in comparison with wt mice. A total of 1024 miRNAs were detected in the heart, of which 256 with the transcript per kilobase million value of > 1 were selected for further analysis. This led to the identification of 21 miRNAs that were significantly dysregulated in the heart of db/db mice as compared to wt controls ( Fig. 1a ).
We previously profiled miRNAs in heart failure patients by microarray 15 . Intersection of the current results from db/db mice with the patient data revealed that, among 21 dysregulated miRNAs, miR-340-5p, miR-34a-5p, and miR-320 were up-regulated in the failing heart of diabetes patients but not in the nondiabetic patients (Online Fig. Ia , Online Table I ). As miR-320 was more abundant than miR-340-5p and miR-34a-5p in human heart (Online Fig. Ib) , we decided to focus on this miRNA for detailed mechanistic study.
By RT-qPCR, we found that the levels of circulating and cardiac miR-320 were increased in heart failure patients with diabetes (Online Fig. Ic , Online Table II and III) as well as in db/db mice ( Fig. 1b ). We further demonstrated that this miRNA was specifically elevated in cardiomyocytes ( Fig. 1c , Online Fig. Id) . We also made similar observations in a high-fat diet (HFD)-induced cardiac dysfunction model (Online Fig.  Ie and If). We further observed that elevated blood glucose preceded the increase in cardiac miR-320 expression ahead of observable cardiac systolic dysfunction ( Fig. 1d- Table IV) . A similar regulation pattern was also observed in db/db mice model at multiple time points (Online Fig. Ij o, Online Table V) . These temporal events in both mice and humans suggest a potential causal role of high glucose-induced expression of miR-320 to the initiation of diabetes induced cardiac dysfunction.
Diabetes-induced cardiac dysfunction is exacerbated by miR-320 overexpression and rescued by miR-320 inhibition.
To demonstrate the causal role of miR-320 in diabetes-induced cardiac dysfunction, we used miR-320overexpressing transgenic (tg) mice to evaluate miR-320 function in high-fat diet-induced cardiac dysfunction model (Online Fig. IIa ). As expected, miR-320 was highly expressed in the heart of these tg mice (Online Fig. IIb and IIc), and high-fat diet exacerbated cardiac dysfunction ( Fig. 2a , Online Table VI) , which was accompanied with increased myocardium size ( In contrast, cardiac function was similar between miR-320 tg and wt mice when fed with normal diet ( Fig. 2a ), indicating that overexpressed miR-320 exerts adverse effects on the heart selectively under diabetic conditions. We further characterized the miR-320 tg mice, showing a greater increase in body weight, glucose levels and insulin resistance than their wt counterparts when fed with high-fat diet (Online Fig. IIe and IIf). To clarify the specific role of miR-320 in the heart, we used a rAAV9 system (with cardiac specificity at 1 × 10 11 vector copy numbers) 16 to express miR-320 or a miR-320 inhibitor based on the tough decoy (TuD) design in db/db mice for long-term (16 weeks) effects. Real-time PCR confirmed that rAAV delivery increased the miR-320 level in the heart (Online Fig. IIg and IIh). Blood glucose level and body weight did not differ among mice 4 months after rAAV delivery (Online Fig. IIi) ; however, cardiac dysfunction was exacerbated by miR-320 overexpression but relieved upon miR-320 inhibition ( Fig. 2d , Online Table VII ). Haematoxylin and eosin staining of myocardial tissue sections and terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labelling indicated that rAAV-miR-320 treatment increased cardiac myocyte size and apoptosis in db/db mice ( Fig. 2e and f), whereas rAAV-miR-320-TuD showed the opposite effects. We additionally explored potential short-term (8 weeks) effects of rAAV-miR-320 treatment on cardiac function. Notably, compared to long-term interventions, the echocardiographic and hemodynamic data from relatively short-term treatment showed similar trends in db/db mice (Online Fig. IIj Online Table VIII) , confirming the consistent and persistent effects of miR-320 in inducing diabetic cardiomyopathy. Importantly, we never saw significant differences on wt mice, indicating the effect of miR-320 on the heart only under diabetic conditions (Online Fig. IIj Online Table VIII) . Interestingly, besides db/db and HFDinduced diabetic models, miR-320 also showed similar regulation on cardiac function in another diabetic model induced by Streptozotocin (STZ) (Online Fig. IIn-p) . Collectively, these results strongly suggest that miR-320 is directly involved in diabetes-induced cardiac dysfunction.
miR-320 acts in the nucleus.
Pre-miRNAs undergo a series of biogenesis steps to generate mature miRNAs, which typically function to regulate gene expression at post-transcription levels in the cytoplasm. As part of our efforts in systematically characterizing biogenesis and function of miR-320 under physiological and pathological conditions, we examined the subcellular localization of miR-320 in diabetic and normal hearts by in situ hybridization. Surprisingly, we noted that miR-320 was present in the nucleus of mouse myocytes (Fig. 3a-c ). This was further confirmed with stem-loop PCR, which specifically detects the mature form of miRNAs, on both cytosolic and nuclear factions (Online Fig. IIIa ). Compared to wt heart, the level of miR-320 was further increased in the nucleus, but remained largely unchanged in the cytosol of db/db mice (Online Fig.  IIIb) . Moreover, cardiomyocytes with elevated levels of nuclear miR-320 also showed TUNEL signals (Online Fig. IIIc and IIId), supporting a potential causal role of miR-320 in diabetes-induced myocytes apoptosis. In sharp contrast, miR-320 was neither co-localized with fibroblast-nor endothelial-specific markers in diabetic heart (Online Fig. IIIe) . We further determined the localization of miR-320 in cultured H9c2 cell lines and neonatal rat ventricular cardiomyocytes (NRVCs), again confirming its nuclear distribution and miR-320 inhibitor treatment significantly decreased the fluorescence intensity of miR-320 FISH signal (Online Fig. IIIf and IIIg). Interestingly, miR-320 was specifically localized in nucleus of NRVCs (CMs), but not non-CMs (Online Fig. IIIh and IIIi). These findings suggest that miR-320 might have a selective role in the nucleus of CMs, which is in line with increasing evidence for nuclear function of miRNAs. To obtain global evidence for this regulatory paradigm, we performed small RNA-seq on fractionated cardiomyocytes, finding that miR-320 was more abundant in the nucleus than in the cytoplasm (Online Fig. IIIj) . Notably, a subset of other miRNAs also showed similar nuclear enrichment (Online If miR-320 was induced in the nucleus of cardiomyocytes from db/db mice, we wondered whether Ago2, a key component of the RNA Induced Silencing Complex (RISC), also showed a detectable increase in the nucleus. Indeed, immunofluorescence and biochemical fractionation experiments revealed the nuclear accumulation of Ago2 in the heart of db/db mice as compared to wt control ( Fig. 3d and e, Online Fig. IV) . We further confirmed the elevated distribution of Ago2 in the nucleus of H9c2 cell lines, human primary cardiomyocytes and neonatal rat ventricular cardiomyocytes when cultured in the presence of high glucose and palmitate (Fig. 3f ). These findings point to a critical role of nuclear miR-320 in cardiomyocytes under diabetes conditions. miR-320 functions in diabetes-induced cardiac dysfunction through induced CD36.
Ago2 has been reported to preferentially associate with active promoters 9 , suggesting a direct role of RISC in transcriptional control. We therefore investigated whether the Ago2-miR-320 complex might interact with specific gene promoters by searching for genes induced by nuclear miR-320 accompanied with diabetes-induced cardiac dysfunction (Fig. 4a ). We reasoned that candidate genes would: 1) be dysregulated in diabetes-induced cardiac dysfunction, 2) show favourable sequence motifs for miR-320 binding near their promoter regions, and 3) respond to miR-320 induction. Using these criteria, we identified potential miR-320 target genes that might be directly responsible for diabetes-induced cardiac dysfunction.
We first performed mRNA microarray analysis of heart tissues from wt and db/db mice, identifying ~600 differentially expressed genes (fold change ≥ 1.5, p < 0.05, Online Fig. Va ). Among these differentially expressed genes, 15 showed binding sites for miR-320 in their promoter regions (sequences 2 kb upstream from the transcription start site), which we selected for further study (Online Fig. Vb ). Of these, the expression of CD36 (a FA translocase) and VLDLR (very low density lipoprotein receptor) were significantly up-regulated in rat H9c2, murine HL-1, human AC16, human primary cardiomyocytes and neonatal rat ventricular cardiomyocytes treated with miR-320 mimic (Fig. 4b-d ). CD36 and VLDLR expression were also increased in db/db mice upon rAAV-miR-320 treatment, an effect that was abrogated by rAAV-miR-320-TuD ( Fig. 4e and f, Online Fig. Vc) .
To establish the functional connection between miR-320 and its candidate target genes, we treated isolated cardiomyocytes with miR-320 mimic or siRNAs against CD36 and VLDLR (siCD36 and siVLDLR). miR-320 or siCD36/VLDLR was efficiently transfected into cardiomyocytes, while no effect on cardiomyocyte apoptosis was observed under normal physiological conditions (Online Fig. VIa and VIb) .
However, when high glucose (33.3 mmol/l) and palmitate (0.5 mmol/l) were used to induce a diabetic state, we detected increased apoptosis with the miR-320 mimic, which could be reversed by the miR-320 inhibitor (Online Fig. VIb) . Importantly, miR-320-induced apoptosis and FFA uptake in cardiomyocytes could be completely or partly blocked by knocking down CD36 or VLDLR, (Fig. 5a and b, Online Fig. VIc) . When miR-320 was inhibited, overexpression of CD36 or VLDLR gave rise to similar results (Online Fig. VId-f ). These data point to the possibility that CD36 and VLDLR may be key downstream effectors of miR-320 in cardiomyocytes under diabetes conditions. The stronger effect of CD36 indicated that the effects conferred by miR-320 were attributed mainly to the induced expression of this gene. We therefore selected CD36 for further functional and mechanistic studies. We used db/db mice and cardiomyocyte-specific troponin T (tnt) vectors (rAAV-tnt) (Online Fig.  VIg) to evaluate whether miR-320 aggravated diabetic cardiomyopathy by modulating CD36 expression in vivo. Sixteen weeks after treatment with rAAV-tnt-miR-320, we detected both increased miR-320 (Online Fig. VIh-j) and CD36 protein (Fig. 5c ) in the heart of db/db mice. While rAAV-tnt-miR-320 and rAAV-tnt-CD36 treatments had no effect on blood glucose levels (Online Fig. VIk and VIl) , such treatments clearly exacerbated cardiac dysfunction in db/db mice (Fig. 5d ). Inhibition of miR-320 with rAAV-miR-320-TUD and shRNA-mediated knockdown of CD36 with the rAAV-tnt-shRNA-CD36 vector abrogated this effect. Moreover, CD36 knockdown blocked rAAV-tnt-miR-320-induced cardiac dysfunction. In contrast, the protective effect of miR-320 inhibition with rAAV-miR-320-TuD was attenuated upon CD36 overexpression through rAAV-tnt-CD36 transduction (Fig. 5d , Online Table IX) . Consistently, we observed coordinated changes in myocardial tissue sections, heart fat deposition, ROS levels and apoptosis under different treatment conditions ( Fig. 5e-g, Online Fig. VIm) . Additionally, we also explored short-term effects (8 weeks) of rAAV-tnt-miR-320 treatment on cardiac function (Online Fig. VIn) . Notably, compared to long-term interventions, the echocardiographic and hemodynamic data from short-term studies showed similar trends in db/db mice (Online Fig. VIo-r , Online Table X ), suggesting the consistent and lasting effects of miR-320/CD36 in diabetic cardiomyopathy.
We further carried out transcriptome analysis of isolated heart tissues from rAAV-tnt-miR-320-TuDtreated db/db mice, confirming decreased CD36 transcription upon miR-320 inhibition relative to control mice (Online Fig. VIs, Supplementary EXCEL) . This analysis further revealed that the miR-320 regulated transcriptome was highly related to diabetic cardiac dysfunction-related pathways according to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis (Online Fig. VIt) . Collectively, these data demonstrated that miR-320 overexpression exacerbated diabetic cardiomyopathy in diabetes mice and the advent effects could be rescued by suppressing either miR-320 or CD36.
Nuclear miR-320 directly activates CD36 transcription.
The mouse CD36 promoter contains seven putative miR-320 binding sites (Fig. 6a ). By chromatin immunoprecipitation sequencing (ChIP-seq), we found that Ago2 interacted with Site 4 in HL-1 cells overexpressing miR-320 ( Fig. 6b, Online Fig. VIIa-d) . We further conformed this result with ChIP-qPCR and obtained similar results on rat H9c2 cardiomyocytes, human primary cardiomyocytes and neonatal rat ventricular cardiomyocytes (Online Fig. VIIe-i) . These data suggest that miR-320 directly targets the miRNA machinery to the CD36 promoter.
To investigate the functional significance of miR-320 regulated expression of CD36, we constructed a pGL3 plasmid harbouring the CD36 promoter. miR-320 overexpression enhanced the fluorescence signal of pGL3-CD36, but not its mutated form (mutation-A at Site 4) (Fig. 6c ). The sequence of Site 4 was conserved between mice and humans (Online Fig. VIIj) . Consistent with the function of miR-320 at the level of transcription, siRNA-mediated knockdown of Ago2 prevented miR-320-induced up-regulation of CD36 in cardiomyocytes (Fig. 6d ). Furthermore, we tempted to functionally rescue miR-320-enhanced CD36 transcription in Ago2-depleted cardiomyocytes with an Ago2 fused to a nuclear localization signal Downloaded from http://ahajournals.org by on November 16, 2019 (Ago2nls). Interestingly, re-expression of nuclear Ago2 restored miR-320-dependant CD36 transcription in adult human AC16 cardiomyocytes as well as in primary Neonatal Rat Ventricular Cardiomyocytes (NRVCs) ( Fig. 6e and f, Online Fig. VIIk) . In contrast, we also engineered a cytosolic form of Ago2 by fusing it to a nuclear export signal (Ago2nes) and found that this cytosolic Ago2 was not able to rescue CD36 transcription in Ago2 knockdown cells (Online Fig. VIIl) . These data provide strong evidence that nuclear miR-320/Ago2 are responsible for CD36 activation in cardiomyocytes. A previous experiment showed that a designer small RNA that targets gene promoter is able to enhance the recruitment of RNA Pol II to activate gene expression 17 . In line with this observation, we also detected an increased association of Ago2 with RNA polymerase II (RNA-POL II) in cardiomyocytes treated with miR-320 mimic (Fig. 6g) . Corroborating with elevated CD36 transcription, we verified elevated RNA Pol II occupancy by ChIP-qPCR on the CD36 promoter in rat H9c2, murine HL-1, rat NRVCs and human primary cardiomyocytes treated with miR-320 mimic (Online Fig. VIIm) . In db/db mice, increased association of Ago2 and RNA-POL II with CD36 promoter were abrogated by rAAV-tnt-miR-320-TuD treatment (Online Fig. VIIn and VIIo). We showed that miR-320 mimic had no effect on the stability of CD36 mRNA (Online Fig. VIIp) . Together, these data suggest that miR-320 directly activate CD36 transcription in the nucleus.
DISCUSSION
Our results demonstrated that miR-320 is up-regulated in the heart by hyperglycaemia, which acts in the nucleus to enhance CD36 transcription. As CD36 is known to promote FA uptake and myocardial lipid deposition, this raises a possibility that gluco-and lipotoxicity might mutually enforce one another, thus collectively contributing to diabetes-induced cardiac dysfunction (Online Fig. VIIq and VIIr) . Importantly, we showed that miR-320 inhibition is able to effectively rescue cardiac dysfunction in diabetic mice.
Interestingly, miR-320 was increased in cardiomyocytes, but remained unchanged in noncardiomyocytes. This has been precedented with other miRNAs. For example, miR-132 was elevated in myocytes but decreased in cardiac fibroblast in pressure overloading-induced heart failure mice 18 . Conversely, miR-21 was reported to show increased expression in fibroblasts but remained unchanged in myocytes during heart failure 19 . Thus, the same miRNA may function in different cell types. Indeed, miR-21 overexpression in fibroblast has been shown to promote cardiac fibrosis, but protect against cardiac hypertrophy in myocytes 8, 19, 20 . Our current findings suggest that miR-320 is another cell type-specific regulator. Further studies will investigate how other miRNAs might be differentially expressed in cardiomyocytes versus other cell types in the heart during development or disease processes.
The divided tasks of miRNAs in different cellular compartments are interesting regulatory paradigms. Most miRNAs are present in both the nucleus and the cytoplasm, with some showing selective nuclear enrichment 21 . For example, miR-29b is mainly nuclear, whereas miR-29a is predominantly cytoplasmic in HeLa cells 22 . The major difference between these two miRNAs is the presence of a hexanucleotide sequence (AGUGUU) at the 3' end of miR-29b and insertion of this motif into an siRNA targeting luciferase was found to be sufficient for nuclear targeting 22 . Other miRNAs containing 3' UGUGUU, ACUGUU, AGAGUU, AGUCUU, AGUGAU, AGUGUA, and AGNGUN sequences are also known to accumulate in the nucleus 23 . We noted related GU-rich motifs in miR-320, but which of these motifs are responsible for nuclear targeting awaits further investigation.
It is currently unclear how exactly miR-320 activates transcription in the nucleus. The mechanism might be related to a phenomenon known as small activating RNAs (saRNAs). It has been previously shown that such designer saRNA is able to target Ago2 to specific gene promoters through inducing the assembly of an RNA-induced transcription activation (RITA) complex, which also contains components of the PAF1 complex 24 . We suspect that miR-320 might activate transcription in a similar manner, and if so, our study would provide an in vivo example for a natural saRNA to activate transcription and link such regulation to an important disease process.
Diabetes-induced cardiac dysfunction is characterised by diastolic dysfunction at early stage, which has been linked to myocardial fibrosis, increased cardiac lipid accumulation, and altered calcium homeostasis 2 . We did not observe myocardial fibrosis in high-fat diet-induced diabetes or db/db mice, consistent with previous studies 25 . Myocardial steatosis (lipid accumulation) is another independent predictor of diastolic dysfunction in type 2 diabetes 26 . We observed increased cardiac lipid accumulation in diabetic mice, which is further enhanced by miR-320, suggesting that miR-320 may exacerbate diastolic dysfunction of diabetic cardiomyopathy by promoting cardiac lipid accumulation.
Metabolic disturbance is aggravated in miR-320 tg mice when combined with high-fat diet-induced diabetes. We previously showed that miR-320 overexpression increased plasma levels of cholesterol and triglycerides in ApoE-null mice 27 . In the present study, we found that cardiac-specific overexpression of miR-320 exacerbated cardiac dysfunction in db/db mice, and conversely, neutralizing miR-320 with rAAVtnt-miR-320-TuD effectively reversed the phenotype of diabetes-induced cardiac dysfunction, suggesting a potential therapeutic strategy for the treatment of diabetes-triggered cardiac dysfunction. In terms of diabetes itself, because cardiac miR-320 overexpression didn't affect blood glucose levels (Online Fig. VIk and VIi), the contribution of miR-320 to diabetes is likely through non-cardiac tissues. Indeed, our unpublished results showed that liver or fat-specific overexpression of miR-320 both increased glucose level and enhanced insulin resistance in db/db mice. In fact, diabetes is well known multiple-tissue disorders, including liver, adipose, pancreas, skeletal muscle and brain, which are far more complicated than just diabetic cardiomyopathy. Therefore, miR-320 might have distinct or even opposite roles in these tissues, which needs further investigation.
Interestingly, cardiac miR-320 overexpression was sufficient to induce CD36 expression under both normal and diabetic conditions, but only exacerbated cardiac function under diabetic condition. In fact, CD36 itself, the direct target of nuclear miR-320, showed a similar effect as miR-320 that CD36 only exacerbated cardiac function in db/db mice but not in normal mice, which was in line with a previous study showing that cardiac CD36 overexpression using AAV9 alone was unable to induce cardiac physiological or morphological changes in normal mice 28 . Moreover, we found that CD36 overexpression in cultured cardiomyocytes enhanced apoptosis only in the presence of FFA and high glucose (Online Fig. VIb) . This is also the case in murine kidney collecting duct cells where over-expressed CD36 alone was found to be insufficient to trigger apoptosis 29 . It appears that excessive CD36 and miR-320 are able to enhance apoptosis and cardiac dysfunction only in the presence of initial stresses, such as FFA and high glucose (Online Fig. VIIq) . This might explain why under physiological conditions, overexpression of CD36 or miR-320 alone appears to be insufficient in induce damages in cultured cells or normal hearts.
Non-esterified fatty acid (NEFA) level and hyperglycaemia are known triggers for the cardiac phenotype in diabetes. CD36 is involved in NEFA uptake into intestinal enterocytes, adipocytes, and skeletal and cardiac myocytes 29 . Our findings suggest a critical role of CD36 in FA transport in the heart, which is consistent with the observation that loss of CD36 could rescue myocardial neutral lipid imbalance and cardiac dysfunction in a mouse model of diabetic cardiomyopathy 30 . Our data suggest that CD36 is an indispensable component of the FA cellular transport system in the heart, consistent with a dominant role of CD36 over other proteins implicated in FFA transport 30 . However, we also noted another FFA transporter, fatty acid binding protein 3, as a target for miR-320 (Online Fig. VIs ), suggesting that miR-320 may modulate multiple related components in the pathway (Online Fig. VIt) , which may collectively contribute to diabetes induced cardiac dysfunction progression. Besides lipid uptake, miR-320 and CD36 (but not VLDLR) also increased lipotoxic catabolite Diacylglycerol (DAG) and ROS levels, decreased mitochondrial ETCs genes expression and ATP production (Online Fig. VIIs) . These mechanisms might thus collectively contribute to miR-320 induced lipotoxicity and explain why apoptosis could be completely blocked by knocking down CD36 but only partly blocked by knocking down VLDLR.
In terms of fatty acids oxidation (FAO), we noted that FAO rates (determined by O 2 consumption) were unaffected by miR-320 or CD36 overexpression (Online Fig. VIIu) . This is actually consistent with a previous study demonstrating that kidney-specific overexpression of CD36 led to considerable accumulation of intracellular lipids, while the quantitative analysis of fatty acid oxidation (FAO) markers indicated almost no change in CD36-transgenic kidney. Another study using CD36 overexpressed primary mouse hepatocytes also suggested that lipid increase was directly related to CD36-mediated fatty acid uptake as opposed to its role in channeling fatty acids to oxidation 31, 32 . Notably, there are also several studies implicating a role of CD36 in promoting FAO. For example, CD36 ablated heart showed decreased FAO in young mice, but no effect on aged mice 33 . In myotubes, CD36 knockdown decreased FAO, however, CD36 knockdown increased FAO when myotubes were permeabilized with digitonin to bypass CD36mediated FA uptake 34 . Another study showed that the effects of CD36 on fatty acid oxidation in muscle cells differed at different concentrations of FFA pre-treated 35 . These results suggest a possibility that CD36 may play a predominant role in FFA uptake, which may indirectly affect FAO. Therefore, our data only suggested that in this particular pathophysiological state, miR-320 and CD36 increased lipids accumulation (Online Fig. VIIt) were likely through activated fatty acids uptake rather than changed FAO (Online Fig.  VIIu) . However, consider the dynamic regulation of FFA on FAO, whether miR-320 or CD36 affected FAO in a shorter/longer time window or another disease model remained to be determined in the future.
Importantly, our data show that the miR-320/CD36 pathway induces both gluco-and lipotoxicity. Metabolic disturbances in the diabetic state include hyperlipidaemia and early hyperinsulinaemia followed by pancreatic β-cell failure, which eventually leads to hyperglycemia 4 . In our high-fat diet-induced diabetic model, we found that miR-320 is up-regulated in the heart after the onset of hyperglycaemia, which increases CD36 expression and lipid uptake by cardiomyocytes, thus perpetuating a negative cycle of lipotoxicity and cardiac dysfunction under diabetes conditions (Online Fig. VIIr) .
Strikingly, we found that exogenous miR-320 TUD (inhibitor) delivered by rAAV was sufficient to rescue cardiac dysfunction in various diabetic models. We noted a previous report by Hideo Iba, suggesting the ability of miRNA-TUD to be directly target to the nucleus 36 . We found that although exogenous miR-320 TUD was detectable both in the nucleus and the cytoplasm, TUD transfection appears to be more effective in reducing nuclear miR-320 (Online Fig. VIIv) . Such selective effect might result from TUD action in the nucleus to reduce nuclear miR-320 or from TUD-mediated sequestration of miR-320 in the cytoplasm, thereby preventing the translocation of miR-320 into the nucleus, possibilities to be differentiated in future studies. Importantly, our data provided concrete evidence that tough-decoy based miR-320 inhibition was sufficient to reduce nuclear miR-320 and rescue cardiac dysfunction in diabetic mice.
In summary, our findings reveal a novel function of miR-320 as a positive regulator of gene transcription and demonstrate that miR-320 inhibition can rescue diabetic cardiomyopathy in diabetic mice. These findings suggest a potential therapeutic strategy for the treatment of diabetes induced cardiac dysfunction by targeting miR-320. (a) Hemodynamic analysis of miR-320 tg and wt mice under normal diet and HFD for 6 months. dp/dt max and dp/dt min, peak instantaneous rate of LV pressure increase and decrease, respectively. wt-CHOW, n = 3; miR-320 tg-CHOW, n = 4; wt-HFD, n = 5; miR-320 tg-HFD, n = 5. 
